[Show abstract][Hide abstract] ABSTRACT: We report a case of postoperative recurrence of liposarcoma of the mesenterium successfully treated by chemotherapy using ifosfamide (IFM) and cisplatin (CDDP). A 58-year-old man presented with a strange feeling in the lower abdomen. Enhanced computed tomography showed enhanced non-epithelial tumor in the pelvic space. The tumor moved on palpation, so we diagnosed liposarcoma from the mesenterium, and resected the tumor on 22 August, 2002. The pleomorphic liposarcoma was 11 x 14 x 7 cm, growing from the mesenterium of the sigmoid colon, and weighed 640 g. We performed re-operation due to pelvic recurrence on 24 March, 2003. On 18 September of the same year, when we performed re-operation again for pelvic recurrence, there were so many recurrences on the mesenterium of small intestine that resection was impossible. We started chemotherapy 3 days later using 3.0 g/body IFM from 1 October 2003, together with 1,800 mg/body mesna for prevention of hemorrhage cystitis. We continued chemotherapy using 3.0 g/body/day IFM together with 1, 800 mg/body/day mesna on an outpatient basis, upon his weekly visit to the hospital. Patient remission was shown by abdominal enhanced computed tomography on 10 December. Some grade 2 alopecia and grade 2 leukopenia occurred, so we changed to chemotherapy once every two weeks. Then, it continued to decrease, without any side effects. The response appeared to be complete on computed tomography in August 2004, and we have been continuing the same chemotherapy without recurrence.
No preview · Article · Jun 2006 · Gan to kagaku ryoho. Cancer & chemotherapy
[Show abstract][Hide abstract] ABSTRACT: A 72-year-old woman admitted for lower abdominal pain. She had a hard, mobile abdominal mass located from the subumbilical region to the pelvic cavity. Abdominal X-ray findings showed ileus of the small intestine. Computed tomography showed an abdominal mass containing air, necessitating surgery under a diagnosis of severe ileus due to the abdominal mass. We found in surgery that the mass originated from the mesentery of the small intestine near the promontrium, which involved part of the small intestine and sigmoid colon, i.e., 2 sites of the small intestine and part of the sigmoid colon. We excised 2 sites of the small intestine and part of the sigmoid colon with the tumor. The abdominal mass was pathologically diagnosed as CD56 + T-cell lymphoma of the small intestine. She refused chemotherapy and alimentary examination, and left hospital. But she caused perforated panperitonitis of the duodenum T-cell lymphoma considered to be simultaneity and multiple. She was died after the operation on the 83rd. The T-cell lymphoma of the small intestine are only 30 cases including our case. Especially, CD56 + T-cell Lymphoma has a high rate of perforation, the prognosis is so poor, and it was considered the disease which should be careful of.
No preview · Article · Jan 2004 · Nippon Shokaki Geka Gakkai zasshi
[Show abstract][Hide abstract] ABSTRACT: The potential role in cell growth of Macrophage migration inhibitory factor (MIF) has been studied, however, the mechanism of its anti-tumor effect is poorly understood. Antisense-MIF plasmids were directly injected into colon 26 tumors embedded in the back of mice. Furthermore, the role of MIF in the cell cycle was assessed with regard to retinoblastoma (Rb) protein and transcription factor E2F. Plasmids containing sense- and antisense-MIF genes were transfected into human colon cancer KM12SM cells in vitro. To examine the Rb protein-E2F pathway, plasmids containing each specific cis-acting enhancer for Rb protein and E2F with luciferase reporter genes, pRB-luc and pE2F-luc, respectively, were used. Antisense MIF treatment significantly reduced the tumor size. In vitro cell proliferation was significantly suppressed by the antisense treatment as examined by BrdU uptake. Transcriptions of Rb protein were 8.4x10(3) (RLU), 9.5x10(3) and 24.3x10(3) in the antisense MIF, PBK, and the sense MIF, respectively. As for E2F, transcription activities were 3.8x10(3), 3.6x10(3) and 7.7x10(3), respectively. These results indicate the possibility that MIF may promote tumor growth, in which the activation-inactivation mechanism of the Rb protein-E2F pathway could be profoundly involved.
No preview · Article · Dec 2002 · International Journal of Molecular Medicine